Ocumension TherapeuticsOCUTF 52 PS Ratio is 4.90 as of Jun. 24, 2026, which is 82% below its 10-year median of 26.78. GuruFocus rates OCUTF with a GF Score™ of 52/100 and a GF Value™ of $2.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 937 Biotechnology companies, Ocumension Therapeutics ranks better than 70.65% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ocumension Therapeutics's share price is $0.70.
Ocumension Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14. Hence, Ocumension Therapeutics's PS Ratio for today is 4.90.
Good Sign:
Ocumension Therapeutics stock PS Ratio (=4.35) is close to 10-year low of 4.35.
The historical rank and industry rank for Ocumension Therapeutics's PS Ratio or its related term are showing as below:
OCUTF'
s PS Ratio Range Over the Past 10 Years
Min: 4.35 Med: 26.78 Max: 592.16
Current: 4.37
During the past 8 years, Ocumension Therapeutics's highest PS Ratio was 592.16. The lowest was 4.35. And the median was 26.78.
OCUTF's PS Ratio is ranked better than 70.65% of 937
companies
in the Biotechnology industry
Industry Median: 9.36
vs OCUTF: 4.37
During the past 8 years, Ocumension Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 101.10% per year. The lowest was 58.70% per year. And the median was 79.40% per year.
Back to Basics: PS Ratio
Ocumension Therapeutics (OTCPK:OCUTF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ocumension Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ocumension Therapeutics's Share Price of today is $0.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ocumension Therapeutics (OCUTF) has a PS Ratio of 4.90 as of Jun. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ocumension Therapeutics and its competitors. This is 82% below median its historical median of 26.78. Over the past decade, Ocumension Therapeutics' PS Ratio has ranged from 4.35 to 592.16. According to the industry distribution chart, Ocumension Therapeutics ranks #275 out of 937 companies in the Biotechnology industry, placing it in the top 29.3%.
Is Ocumension Therapeutics' PS Ratio too high?
Ocumension Therapeutics' current PS Ratio of 4.90 is 82% below median its 10-year median of 26.78. Over the past 10 years, this metric has ranged from a low of 4.35 to a high of 592.16. The Biotechnology industry median PS Ratio is 9.36. Ocumension Therapeutics' value of 4.90 is 47.6% below this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #275 out of 937 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocumension Therapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #275 out of 937 companies for PS Ratio. This puts Ocumension Therapeutics in the upper half of its industry. The industry median PS Ratio is 9.36. Ocumension Therapeutics' value of 4.90 is 47.6% below this benchmark. Historically, Ocumension Therapeutics' own PS Ratio has ranged from 4.35 to 592.16 over the past decade. While the company's 10-year median is 26.78 vs. the industry median of 9.36, Ocumension Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.36, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current PS Ratio of 4.90 is 47.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current PS Ratio is 4.90, which is 82% below median its own 10-year median of 26.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.82, compared to a current price of $0.70 — trading 75.2% below its estimated fair value. The current PS Ratio is 4.90, which is 82% below median its 10-year median of 26.78 and 47.6% below the Biotechnology industry median of 9.36. Ocumension Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current PS Ratio is 4.90 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 75.2% below its estimated GF Value™ of $2.82.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
PS Ratio: 4.90 (82% below median its 10-year median of 26.78)
GF Value™: $2.82 vs. price of $0.70 (75.2% below fair value)
Industry Position: 47.6% below the Biotechnology median (#275 of 937)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score
Get the complete analysis for OCUTF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
